866-997-4948(US-Canada Toll Free)

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Therapeutic Area

No. of Pages : 95 Pages


Global Markets Directs, Uterine Leiomyoma (Uterine Fibroids) Pipeline Review, H1 2015, provides an overview of the Uterine Leiomyoma (Uterine Fibroids)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Uterine Leiomyoma (Uterine Fibroids) Overview 8
Therapeutics Development 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 10
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 11
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 13
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 17
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 18
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 19
AbbVie Inc. 19
Bayer AG 20
BioSpecifics Technologies Corp. 21
Dongkook Pharmaceutical Co., Ltd. 22
Euroscreen S.A. 23
Kissei Pharmaceutical Co., Ltd. 24
Laboratoire HRA Pharma 25
Neurocrine Biosciences, Inc. 26
Novartis AG 27
Repros Therapeutics Inc. 28
Takeda Pharmaceutical Company Limited 29
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
collagenase clostridium histolyticum - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
elagolix sodium - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ESN-364 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
EVE-104 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
KLH-2109 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LFA-102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
mifepristone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
relugolix - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
telapristone acetate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
triptorelin pamoate biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ulipristal acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
vilaprisan - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates 62
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects 82
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products 83
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones 84
Featured News & Press Releases 84
Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids 84
Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design 84
Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids 84
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 86
Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 86
Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 87
Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 88
Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 89
Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 90
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 92

Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Table


Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2015 9
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H1 2015 19
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2015 20
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H1 2015 21
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 22
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H1 2015 23
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 24
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1 2015 25
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Neurocrine Biosciences, Inc., H1 2015 26
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Novartis AG, H1 2015 27
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H1 2015 28
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H1 2015 62
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2015 82
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2015 83

List of Chart


Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2015 9
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Products, H1 2015 16
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 31
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Top 10 Molecule Types, H1 2015 37
Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *